Although most acute myeloid leukemia (AML) patients can achieve complete remission (CR) induced by standardized chemotherapy, but the relapse rate after remission remains high. The key reason is its high heterogeneity in cytogenetics and molecular biology. There are evidences show that minimal residual disease (MRD) is closely associated with disease recurrence, so that, finding specific genetic and molecular biological changes as new targets for MRD detection has become a research hotspot in recent years. In this review the intrinsic relationship between relapse of AML and MRD detection of specific molecular events, the application of these new targets in MRD detection and their targeted therapies according to the latest guidelines, so as to achieve the optimal treatment in CR phase.
题目: MRD检测新靶点在急性髓系白血病复发中的研究现状.
摘要: 大多数急性髓系白血病(AML)患者虽然在标准化疗方案诱导下可达到完全缓解（CR），但缓解后的复发率仍高居不下，最关键的原因在于其在细胞遗传学和分子生物学方面的高度异质性。有证据表明，微小残留病（MRD）与疾病复发密切相关，因此，寻找特定的遗传学和分子生物学改变作为MRD检测的新靶点成为近些年的研究热点。本文旨在阐述AML复发与特定分子事件MRD检测的内在联系，并根据最新指南对这些新靶点在MRD检测中的应用及其靶向治疗进行综述，以期在CR期给予最优治疗方案.